Correlation of DNA Repair Gene XRCC1 Single Nucleotide Polymorphism with Sensitivity of Nasopharyngeal Carcinoma Patients to Platinum Chemotherapy

LIU Longjing; LI Guisheng; CHEN Haihui

doi:10.3971/j.issn.1000-8578.2015.07.009

Cancer Research on Prevention and Treatment > 2015 > 42(07): 681-686. > DOI: 10.3971/j.issn.1000-8578.2015.07.009

LIU Longjing, LI Guisheng, CHEN Haihui. Correlation of DNA Repair Gene XRCC1 Single Nucleotide Polymorphism with Sensitivity of Nasopharyngeal Carcinoma Patients to Platinum Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2015, 42(07): 681-686. DOI: 10.3971/j.issn.1000-8578.2015.07.009

Citation:

PDF (1743 KB)

Correlation of DNA Repair Gene XRCC1 Single Nucleotide Polymorphism with Sensitivity of Nasopharyngeal Carcinoma Patients to Platinum Chemotherapy

Department of Medical Oncology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545005, China (*: Contributed Equally as First Author)

More Information

Received Date: May 06, 2014
Revised Date: September 03, 2014

Graphical Abstract

Abstract

Abstract

Objective To explore the correlation of codon194 and codon399 single nucleotide polymorphisms (SNP) of DNA repair gene X-ray repair cross-complementing gene 1(XRCC1) with the sensitivity to platinum chemotherapy in nasopharyngeal carcinoma(NPC)patients. Methods The biopsy specimens were obtained from NPC patients diagnosed by nasopharyngeal endoscopy in The Fourth Affiliated Hospital of Guangxi Medical University from September 1 2012 to December 31 2013. XRCC1 SNP at codon194 and codon399 in NPC patients were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). After 2 periods of PF(cisplatin+5-fluorouracil) induction chemotherapy, MRI was taken to assess the efficacy according to RECIST 1.1 standard, evaluate the relationship between SNP and the sensitivity of chemotherapy in nasopharyngeal cancer patients. Results The patients with XRCC1 codon399 Gln/Gln polymorphisms were 3.500 times as sensitive to the chemotherapy as the patients with Arg/Arg genotype(P<0.05). The patients with XRCC1 codon399 Gln/Gln polymorphisms were 3.274 times as sensitive to the chemotherapy as the patients with (Arg/Arg+Arg/Gln) genotype(P<0.05). The sensitivity to chemotherapy wasn't significant different among the patients with XRCC1 codon194 Arg/Arg, Arg/Trp,Trp/Trp polymorphisms(P>0.05). Conclusion XRCC1 codon399 SNP might be a useful predictive marker in NPC patients treated with cisplatin-based chemotherapy.
- XRCC1,
- Single nucleotide polymorphism(SNP),
- Nasopharyngeal carcinoma(NPC),
- Chemotherapy

FullText(HTML)

References (31)

References

[1]	Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China[J]. Int J Radiat Oncol Biol Phys, 2008, 71(5): 1356-64.
[2]	Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients[J]. Inter J Radiat Oncol Biol Phys, 2006, 64(1): 47-56.
[3]	Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma[J]. J Natl Cancer Inst, 2010, 102(15): 1188-98.
[4]	Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage Ⅲ and Ⅳ nasopharyngeal cancer of the endemic variety[J]. J Clin Oncol, 20 05, 23(27): 6730-8.
[5]	Lee AW, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group[J]. J Clin Oncol, 2005, 23(28): 6966-75.
[6]	Fang Q, Inanc B, Schamus S, et al. HSP90 regulates DNA repair via the interaction between XRCC1 and DNA polymerase beta[J]. Nature Communications, 2014, 5: 5513.
[7]	Weinshilboum R. Inheritance and drug response[J]. N Engl J Med, 20 03, 348(6): 529-37.
[8]	Jiang J, Liang J, Yao R, et al. Polymorphisms of ERCC1, XPD, XRCC1 and XPG predict clinical outcome in advanced gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population[J]. Clin Oncol Cancer Res, 2009, 6(5): 32 8-36.
[9]	Wei SZ, Zhan P, Shi MQ, et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis[J]. Med Oncol, 2011, 28(1): 315-21.
[10]	Liu L, Yuan P, Wu C, et al. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy[J]. Lung Cancer, 2011, 73(1): 110-5.
[11]	Artac M, Bozcuk H, Pehlivan S, et al. The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens[J]. J Cancer Res Clin Oncol, 2010, 136(6): 803-9.
[12]	Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy[J]. J Clin Oncol, 2004, 22(13): 2594-601.
[13]	Kong L, Zhang YW, Hu CS, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma[J]. Chin J Cancer, 2010, 29(5): 551-5.
[14]	Airoldi M, Gabriele P, Gabriele AM, et al. Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin+ taxol in locally advanced nasopharyngeal carcinoma[J]. Cancer Chemother Pharmacol, 20 11, 67(5): 1027-34.
[15]	Lu X, Xiao S, Jin C, et al. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis[J]. J Clin Lab Anal, 2012, 26(1): 10-5.
[16]	Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years[J]. World J Gastroenterol, 2014, 20(29): 9775-827.
[17]	Jayachandran G, Ueda K, Wang B, et al. NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway[J]. PloS One, 2010, 5(8): e11994.
[18]	Caldecott KW, Aoufouchi S, Johnson P, et al. XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADPribose) polymerase, and DNA ligase Ⅲ is a novel molecular 'nicksensor' in vitro[J]. Nucleic Acids Res, 1996, 24(22): 4387-94.
[19]	Shen MR, Jones IM, Mohrenweiser H. Nonconservative aminoacid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans[J]. Cancer Res, 1998, 58(4): 604-8.
[20]	Du Y, He Y, Mei Z, et al. Association between genetic polymorphisms in XPD and XRCC1 genes and risks of non-small cell lung cancer in East Chinese Han population[J]. Clin Respir J, 20 14. [Epub ahead of print]
[21]	Ramadan RA, Desouky LM, Elnaggar MA, et al. Association of DNA repair genes XRCC1 (Arg399Gln), (Arg194Trp) and XRCC3 (Thr241Met) polymorphisms with the risk of breast cancer: a case-control study in Egypt[J]. Genet Test Mol Biomarkers, 2014, 18(11): 754-60.
[22]	Surdu S, Fitzgerald EF, Bloom MS, et al. Polymorphisms in DNA repair genes XRCC1 and XRCC3, occupational exposure to arsenic and sunlight, and the risk of non-melanoma skin cancer in a European case-control study[J]. Environ Res, 2014, 134: 382-9.
[23]	Chiang CI, Huang YL, Chen WJ, et al. XRCC1 Arg194Trp and Arg399Gln polymorphisms and arsenic methylation capacity are associated with urothelial carcinoma[J]. Toxicol Appl Pharmacol. 20 14, 279(3): 373-9.
[24]	Cui Z, Yin Z, Li X, et al. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis[J]. BMC Cancer, 2012, 12: 71.
[25]	Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer[J]. Clin Lung Cancer, 2009, 10(2): 11 8-23.
[26]	Stoehlmacher J, Ghaderi V, Iobal S, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer[J]. Anticancer Res, 2001, 21(4B): 30 75-9.
[27]	Chen C, Wang F, Wang Z, et al. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy[J]. Cancer Chemother Pharmacol, 2013, 72(2): 31 5-22.
[28]	Quintela-Fandino M, Hitt R, Medina PP, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy[J]. J Clin Oncol, 2006, 24(26): 4333-9.
[29]	Hong CY, Xu Q, Yue Z, et al. Correlation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism[J]. Ai Zheng, 2009, 28(12): 1291-7. [洪成雨, 徐倩, 岳峥, 等. 非小细胞肺癌NP方案化疗敏感性与DNA修复基因XRCC1多态性的关系[J]. 癌症, 2009, 28(12): 1291-7.]
[30]	Wang ZH, Miao XP, Tan W, et al. Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer[J]. Ai Zheng, 2004, 23(8): 865-8. [王中华, 缪小平, 谭文, 等. XRCC1 单核苷酸多态与晚期非小细胞肺癌对铂类药物化疗敏感性的相关性[J]. 癌症, 2004, 23(8): 865-8.]
[31]	Ruzzo A, Graziano F, Kawakami K, et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy[J]. J Clin Oncol, 20 06, 24(12): 1883-91.

[1]	HE Yang, YANG Runfeng, ZHOU Yingying, XU Qian, YAN Hao, JIANG Lei, JIANG Xiaohui, HUANG Yi. Effect of Aprepitant on Chemotherapy-induced Adverse Reactions in Gynecological Malignancy Patients[J]. Cancer Research on Prevention and Treatment, 2018, 45(11): 913-916. DOI: 10.3971/j.issn.1000-8578.2018.18.0265
[2]	LI Daojun, XU Xinhua, ZHANG Jianyu, LI Cong. Clinical Observation of Olanzapine in Treatment of Nausea and Vomiting Caused by Opioid Analgesics[J]. Cancer Research on Prevention and Treatment, 2018, 45(5): 326-328. DOI: 10.3971/j.issn.1000-8578.2018.17.1275
[3]	DONG Shuang, WANG Jun, HU Sheng, LIAO Guoxiang, RAN Fengming. Aprepitant versus Olanzapine for Prevention of Nausea and Vomiting Induced by Multi-day Chemotherapy in Female Lung Cancer or Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(5): 356-359. DOI: 10.3971/j.issn.1000-8578.2017.05.009
[4]	LI Quanfu, Jin gaowa, WANG Wenjuan, JIANG Caihong, DENG Shuqin, LI Hui, CHEN Feng, BAI Xiaojun, CHEN Gang, HU Yuliang, ZHAO Jun, Dalenggaowa, Wuyungaowa. Clinical Observation of Neurokinin-1 Antagonist Preventing Multiple-day Chemotherapy-induced Nausea and Vomiting[J]. Cancer Research on Prevention and Treatment, 2017, 44(4): 290-294. DOI: 10.3971/j.issn.1000-8578.2017.04.011
[5]	LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007
[6]	DONG Shuang, YU Shiying. A Study of Chemotherapy-induced Nausea and Vomiting Involving Different Dosage Regimens of Cisplatin[J]. Cancer Research on Prevention and Treatment, 2013, 40(09): 890-893. DOI: 10.3971/j.issn.1000-8578.2013.09.016
[7]	Xu Lu, Li Chunlai, Li Ling. A Constructive Experimental Study on Prevention of Chemotherapy-induced Nausea and Vomiting by Ginger-partitioned Moxibustion on Acupoint of Zusanli[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 710-712. DOI: 10.3971/j.issn.1000-8578.2012.06.024
[8]	XU Shu, LI Hong, SONG Yu-hong, LI Bin, CAI Hong-bing. Clinical Comparative of Tropisetron Hydrochloride with or without Traditional Chinese Medicine Compound in Prevention of Chemotherapy-induced Nausea and Emesis[J]. Cancer Research on Prevention and Treatment, 2009, 36(09): 787-790. DOI: 10.3971/j.issn.1000-8578.2009.09.021
[9]	MA Lei, MA Hai-long, ZHAO Xu-lin, et al. A Clinical Observation of Tropisetron in Combination with Dexame thasone and Methclopramide in the prevention of High Dose Cisplatin- induced Delayed Nausea and Emesis[J]. Cancer Research on Prevention and Treatment, 2001, 28(06): 469-470. DOI: 10.3971/j.issn.1000-8578.474
[10]	Chen Zhendong, . Medroxyprogesterone Acetate with Antiemetics: Efficacy in ControllingAnorexia, Nausea and Vomiting Induced by Chemotherapy[J]. Cancer Research on Prevention and Treatment, 1996, 23(2): 102-103.

Cited By

Get Citation

PDF

XML

Article views (1385) PDF downloads (580)

Turn off MathJax

Article Contents

Abstract

References

Correlation of DNA Repair Gene XRCC1 Single Nucleotide Polymorphism with Sensitivity of Nasopharyngeal Carcinoma Patients to Platinum Chemotherapy

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Correlation of DNA Repair Gene XRCC1 Single Nucleotide Polymorphism with Sensitivity of Nasopharyngeal Carcinoma Patients to Platinum Chemotherapy

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content